Dong-Hun Shin

Joo-Seop Chung1
Joong-Keun Kim1
1Joo-Seop Chung
1Joong-Keun Kim
Learn More
BACKGROUND Although adding rituximab to the chemotherapy regimen of cyclophosphamide, vincristine, doxorubicin, and prednisone (R-CHOP) has improved clinical outcomes of patients with diffuse large B-cell lymphoma (DLBCL), several recent studies have shown that the effect of rituximab is dominantly in the non-germinal center (non-GC) subtype compared to the(More)
  • 1